Kite Pharma, Inc. 4
4 · Kite Pharma, Inc. · Filed May 9, 2017
Insider Transaction Report
Form 4
BONDERMAN DAVID
Director
Transactions
- Purchase
Common Stock
2017-05-09$70.15/sh+3,815$267,622→ 2,408,084 total(indirect: See footnote) - Purchase
Common Stock
2017-05-09$68.84/sh+46,185$3,179,375→ 2,404,269 total(indirect: See footnote)
Holdings
- 1,950
Common Stock
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $68.64 to $69.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
- [F2]The securities are held in the name of the Bonderman Family Limited Partnership ("BFLP") of which Mr. Bonderman is a limited partner. Wildcat Capital Management, LLC ("Wildcat") has dispositive and voting power over the shares held by BFLP pursuant to the terms of an investment management agreement to which Wildcat, Mr. Bonderman and BFLP are parties. Mr. Bonderman disclaims beneficial ownership of such shares held by BFLP except to the extent of his pecuniary interest therein.
- [F3]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $69.84 to $70.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.